Back
Supernus Pharmaceuticals Stock Predictions
Spencer Rascoff co-founded Zillow, scaling it to a $16B valuation. But everyday investors couldn't invest until the IPO, missing early gains.
This is a paid advertisement for Pacaso's Regulation A offering. Please read the offering circular and related risks at invest.pacaso.com.
Sell
40
SUPN
Supernus Pharmaceuticals
Last Price:
$31.73
Seasonality Move:
11.77%
7 Day Trial
ALL ACCESS PASS
$
7
Top investors are buying this "unlisted" stock
This is a paid advertisement for Pacaso's Regulation A offering. Please read the offering circular and related risks at invest.pacaso.com.Supernus Pharmaceuticals Stock Forecast
-
Over the next 52 weeks, Supernus Pharmaceuticals has on average historically risen by 22.3% based on the past 12 years of stock performance.
-
Supernus Pharmaceuticals has risen higher in 8 of those 12 years over the subsequent 52-week period, corresponding to a historical accuracy of 66.67%
-
Is Supernus Pharmaceuticals Stock Undervalued?The current Supernus Pharmaceuticals [SUPN] share price is $32.15. The Score for SUPN is 40, which is 20% below its historic median score of 50, and infers higher risk than normal.
-
SUPN is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.
Will Supernus Pharmaceuticals Stock Go Up Next Year?
-
Over the next 52 weeks, Supernus Pharmaceuticals has on average historically risen by 22.3% based on the past 12 years of stock performance.
Supernus Pharmaceuticals Stock Rating
Sell
40
Supernus Pharmaceuticals (SUPN)
is a Sell
Is Supernus Pharmaceuticals overpriced?
-
Supernus Pharmaceuticals has risen higher in 8 of those 12 years over the subsequent 52-week period, corresponding to a historical accuracy of 66.67%
Supernus Pharmaceuticals Stock Price History
Stock Information
Stock Info
Exchange:
NASDAQ
Country:
United States
Industry:
Pharmaceuticals
Sector:
Health Care
Type:
stock
Website:
supernus.com
52-Week Data
52-Week High:
40.28
52-Week Low:
25.53
Prediction Charts
Market Cap:
1.8B
Price in USD:
32.15
Volume:
433.1K
Beta:
1.09
Technical Analysis
SMA50:
31.89
SMA100:
34.51
SMA200:
34.05
52-Wk Change:
11.02%
Stock Predictions
-
Is Supernus Pharmaceuticals stock public?Yes, Supernus Pharmaceuticals is a publicly traded company.
-
What is the Supernus Pharmaceuticals stock quote today?The Supernus Pharmaceuticals stock price is 32.15 USD today.
-
How to buy Supernus Pharmaceuticals stock online?You can buy Supernus Pharmaceuticals shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
14-Day Historical Data
| Date | Opening | Closing | Minimum | Maximum |
|---|---|---|---|---|
| Apr-23 | 31.31 | 30.84 | 31.64 | 30.67 |
| Apr-24 | 30.84 | 31.35 | 31.45 | 30.42 |
| Apr-25 | 31.41 | 32.22 | 32.36 | 31.16 |
| Apr-28 | 32.48 | 32.25 | 32.57 | 31.88 |
| Apr-29 | 32.20 | 32.49 | 32.60 | 31.95 |
| Apr-30 | 32.60 | 32.48 | 32.80 | 32.16 |
| May-1 | 31.72 | 32.45 | 32.63 | 31.35 |
| May-2 | 32.70 | 32.84 | 33.28 | 32.43 |
| May-5 | 32.90 | 32.39 | 33.02 | 31.82 |
| May-6 | 32.37 | 32.43 | 32.78 | 31.70 |
| May-7 | 30.04 | 30.94 | 32.26 | 29.16 |
| May-8 | 30.83 | 31.54 | 31.91 | 30.44 |
| May-9 | 31.54 | 31.70 | 32.22 | 31.22 |
| May-12 | 32.20 | 32.15 | 32.32 | 31.59 |
Supernus Pharmaceuticals Earnings
Supernus Pharmaceuticals Earnings Report: Per Share Supernus Pharmaceuticals Earnings Q1 Q2 Q3 and Q4 last year and next year.
Supernus Pharmaceuticals Forecast Revenue Growth
Supernus Pharmaceuticals Stock Analysis: Historical quarterly revenues per share for Supernus Pharmaceuticals and historical quarterly revenue growth:
-
Analysts estimate an earnings decrease this quarter of $0.09 per share, an increase next quarter of $0.07 per share, a decrease this year of $0.80 per share, and an increase next year of $0.52 per share.
* Supernus Pharmaceuticals stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.